{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T02:05:45Z","timestamp":1780106745738,"version":"3.54.0"},"reference-count":43,"publisher":"MDPI AG","issue":"14","license":[{"start":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T00:00:00Z","timestamp":1721260800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Italian Ministry of Health"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Epithelial ovarian cancer (EOC) is the deadliest gynecological malignancy worldwide. Brain metastasis (BM) is quite an uncommon presentation. However, the likelihood of central nervous system (CNS) metastasization should be considered in the context of disseminated disease. The therapeutic management of BMs is an unmet clinical need, to date. We identified, across different cancer centers, six cases of both BRCA wild-type and BRCA-mutated EOCs spreading to the CNS. They presented either with a single brain lesion or with multiple lesions and most of them had intracranial-only disease. All cases received Poly-ADP ribose polymerase inhibitor (PARPi) maintenance, as per clinical practice, for a long time within a multimodal treatment approach. We also provide an insight into the available body of work regarding the management of this intriguing disease setting, with a glimpse of future therapeutic challenges. Despite the lack of unanimous guidelines, multimodal care pathways should be encouraged for the optimal disease control of this unfortunate patient subset. Albeit not being directly investigated in BM patients, PARPi maintenance is deemed to have a valuable role in this setting. Prospective research, aimed to implement worthwhile strategies in the multimodal patient journey of BMs from EOC, is eagerly awaited.<\/jats:p>","DOI":"10.3390\/ijms25147887","type":"journal-article","created":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T16:51:12Z","timestamp":1721321472000},"page":"7887","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["PARP Inhibitors in Brain Metastases from Epithelial Ovarian Cancer through a Multimodal Patient Journey: Case Reports and Literature Review"],"prefix":"10.3390","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3491-4666","authenticated-orcid":false,"given":"Simona","family":"Frezzini","sequence":"first","affiliation":[{"name":"Medical Oncology 3 Unit, Veneto Institute of Oncology IOV\u2014IRCCS, 35128 Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Tasca","sequence":"additional","affiliation":[{"name":"Medical Oncology 2 Unit, Veneto Institute of Oncology IOV\u2014IRCCS, 35128 Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Borgato","sequence":"additional","affiliation":[{"name":"Medical Oncology Unit, Ospedale San Bortolo, 36100 Vicenza, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Sartor","sequence":"additional","affiliation":[{"name":"Medical Oncology Unit, Ospedale di Camposampiero, ULSS 6 Euganea, 35131 Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2909-3699","authenticated-orcid":false,"given":"Annamaria","family":"Ferrero","sequence":"additional","affiliation":[{"name":"Academic Department Gynecologic Oncology, Mauriziano Hospital, University of Torino, 10124 Torino, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grazia","family":"Artioli","sequence":"additional","affiliation":[{"name":"Medical Oncology Unit, Azienda ULSS 2 Marca Trevigiana, 31100 Treviso, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Modena","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, IRCCS Ospedale Sacro Cuore Don Calabria, 37024 Negrar, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Baldoni","sequence":"additional","affiliation":[{"name":"Oncology and Hematology Department, Mirano AULSS3 Serenissima, 30035 Mirano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,7,18]]},"reference":[{"key":"ref_1","unstructured":"Birbrair, A. (2021). Ovarian cancer stem cell heterogeneity. Stem Cells Heterogeneity in Cancer, Springer."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.annonc.2023.11.015","article-title":"ESGO\u2013ESMO\u2013ESP consensus conference recommendations on ovarian cancer: Pathology and molecular biology and early, advanced, and recurrent disease","volume":"35","author":"Ledermann","year":"2024","journal-title":"Ann. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"National Comprehensive Cancer Network (2024). Ovarian Cancer Including Fallopian Tube Cancer and Primary Peritoneal Cancer, National Comprehensive Cancer Network. NCCN Practice Guidelines, Version 1.","DOI":"10.6004\/jnccn.2023.5017"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Scotto, G., Borella, F., Turinetto, M., Tuninetti, V., Valsecchi, A.A., Giannone, G., Cosma, S., Benedetto, C., and Valabrega, G. (2021). Biomarkers of central nervous system involvement from epithelial ovarian cancer. Cells, 10.","DOI":"10.3390\/cells10123408"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Alizzi, Z., Roxburgh, P., Cartwright, D., McLaren, A., Park, S., Jones, R., Greening, S., Hudson, E., Green, C., and Gray, S. (2023). Description of a retrospective cohort of epithelial ovarian cancer patients with brain metastases: Evaluation of the role of PARP inhibitors in this setting. J. Clin. Med., 12.","DOI":"10.3390\/jcm12072497"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1200\/JCO.2002.20.4.982","article-title":"Epithelial ovarian cancer metastasizing to the brain: A late manifestation of the disease with an increasing incidence","volume":"20","author":"Kolomainen","year":"2002","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.ygyno.2016.09.025","article-title":"Brain metastases in patients with EOC: Clinico-pathological and prognostic factors. A multicentric retrospective analysis from the MITO group (MITO 19)","volume":"143","author":"Marchetti","year":"2016","journal-title":"Gynecol. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1136\/ijgc-2020-001288","article-title":"Manage wisely: Poly(ADP-ribose) polymerase inhibitor (PARPi) treatment and adverse events","volume":"30","author":"Madariaga","year":"2020","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.ygyno.2012.11.001","article-title":"Clinicopathologic features of brain metastases from gynecologic malignancies: A retrospective study of 139 cases (KCOG-G1001s trial)","volume":"128","author":"Nasu","year":"2013","journal-title":"Gynecol. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1186\/s13256-023-04211-6","article-title":"Cerebellar metastasis of ovarian cancer: A case report","volume":"17","author":"Cabitza","year":"2023","journal-title":"J. Med. Case Rep."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11060-014-1447-9","article-title":"Brain metastasis from ovarian cancer: A systematic review","volume":"119","author":"Pakneshan","year":"2014","journal-title":"J. Neuro-Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s11095-018-2455-9","article-title":"Barriers to Effective Drug Treatment for Brain Metastases: A Multifactorial Problem in the Delivery of Precision Medicine","volume":"35","author":"Kim","year":"2018","journal-title":"Pharm. Res."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1080\/0284186X.2022.2066985","article-title":"Brain metastases in patients with ovarian cancer","volume":"61","author":"Limon","year":"2022","journal-title":"Acta Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1136\/ijgc-2020-002225","article-title":"Long-term response to olaparib in BRCA 1-related ovarian cancer with brain metastases","volume":"31","author":"Gallego","year":"2021","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1136\/ijgc-2020-001849","article-title":"Across barriers: Poly ADP-ribose polymerase inhibitors beyond progression in high grade serous ovarian cancer with brain metastases","volume":"31","author":"Kasherman","year":"2021","journal-title":"Int. J. Gynecol. Cancer Off. J. Int. Gynecol. Cancer Soc."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.ygyno.2019.05.004","article-title":"Brain metastasis in epithelial ovarian cancer by BRCA1\/2 mutation status","volume":"154","author":"Stasenko","year":"2019","journal-title":"Gynecol. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1097\/IGC.0000000000001341","article-title":"Treatment results and prognostic factors of brain metastases from ovarian cancer: A single institutional experience of 56 patients","volume":"28","author":"Kwon","year":"2018","journal-title":"Int. J. Gynecol. Cancer Off. J. Int. Gynecol. Cancer Soc."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"12979","DOI":"10.2147\/OTT.S281302","article-title":"Niraparib as maintenance therapy in germline ATM-mutated and somatic BRCA2-mutated ovarian cancer with brain metastases: A case report and literature review","volume":"13","author":"Wu","year":"2020","journal-title":"OncoTargets Ther."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1097\/COC.0b013e3181ec5f4b","article-title":"Multidrug resistance gene (MDR-1) and risk of brain metastasis in epithelial ovarian, fallopian tube, and peritoneal cancer","volume":"34","author":"Matsuo","year":"2011","journal-title":"Am. J. Clin. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.semcancer.2020.08.005","article-title":"Lessons learned from understanding chemotherapy resistance in epithelial tubo-ovarian carcinoma from BRCA1and BRCA2 mutation carriers","volume":"77","author":"Amuzu","year":"2021","journal-title":"Semin. Cancer Biol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.annonc.2021.11.013","article-title":"European experts\u2019 consensus: BRCA\/homologous recombination deficiency testing in first-line ovarian cancer","volume":"33","author":"Vergote","year":"2022","journal-title":"Ann. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1097\/IGC.0000000000000489","article-title":"Epithelial ovarian cancer metastatic to the central nervous system and a family history concerning hereditary breast and ovarian cancer\u2014A potential relationship","volume":"25","author":"Jernigan","year":"2015","journal-title":"Int. J. Gynecol. Cancer Off. J. Int. Gynecol. Cancer Soc."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.ygyno.2019.03.004","article-title":"Increased risk of brain metastases in ovarian cancer patients with BRCA mutations","volume":"153","author":"Ratner","year":"2019","journal-title":"Gynecol. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s11060-017-2459-z","article-title":"Next-Generation Sequencing-based genomic profiling of brain metastases of primary ovarian cancer identifies a high number of BRCA-mutations","volume":"133","author":"Balendran","year":"2017","journal-title":"J. Neuro-Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s11523-023-00970-w","article-title":"PARP inhibitors in ovarian cancer: A review","volume":"18","author":"Krivak","year":"2023","journal-title":"Target. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e230738","DOI":"10.1136\/bcr-2019-230738","article-title":"Niraparib as maintenance therapy in a patient with ovarian cancer and brain metastases","volume":"12","author":"Gray","year":"2019","journal-title":"BMJ Case Rep."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"37080","DOI":"10.18632\/oncotarget.26354","article-title":"A comparative pharmacokinetic study of PARP inhibitors demonstrates favorable properties for niraparib efficacy in preclinical tumor models","volume":"9","author":"Sun","year":"2018","journal-title":"Oncotarget"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"B168","DOI":"10.1158\/1535-7163.TARG-15-B168","article-title":"Abstract B168: The PARP inhibitor, niraparib, crosses the blood brain barrier in rodents and is efficacious in a BRCA2-mutant intracranial tumor model","volume":"14","author":"Mikule","year":"2015","journal-title":"Mol. Cancer Ther."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.trecan.2019.12.004","article-title":"Therapeutic application of PARP inhibitors in neuro-oncology","volume":"6","author":"Ning","year":"2020","journal-title":"Trends Cancer"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1200\/JCO.2024.42.16_suppl.2013","article-title":"A phase II trial of olaparib and durvalumab in patients with recurrent IDH-mutated gliomas","volume":"42","author":"Wang","year":"2024","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1200\/JCO.2024.42.16_suppl.2002","article-title":"Niraparib efficacy in patients with newly-diagnosed glioblastoma: Clinical readout of a phase 0\/2 \u201ctrigger\u201d trial","volume":"42","author":"Sanai","year":"2024","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Zhang, Z., Xu, M., Sakandar, A., Du, X., He, H., He, W., Li, D., and Wen, Q. (2022). Successful treatment of a patient with brain metastasis from ovarian cancer with BRCA wild type using niraparib: A case report and review of the literature. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.873198"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"818","DOI":"10.21037\/apm-21-113","article-title":"Successful treatment of a patient with brain metastases from endometrial cancer using Niraparib: A case report","volume":"10","author":"Wang","year":"2021","journal-title":"Ann. Palliat. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.gore.2016.10.004","article-title":"Olaparib treatment for BRCA-mutant ovarian cancer with leptomeningeal disease","volume":"18","author":"Bangham","year":"2016","journal-title":"Gynecol. Oncol. Rep."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1111\/jog.13851","article-title":"Durable response by olaparib for a Japanese patient with primary peritoneal cancer with multiple brain metastases: A case report: Durable response by olaparib","volume":"45","author":"Sakamoto","year":"2019","journal-title":"J. Obstet. Gynaecol. Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"iii12","DOI":"10.1093\/noajnl\/vdab071.049","article-title":"THER-02. PARP inhibitor tolerability and impact on progression-free survival in patients with high-grade, ovarian carcinoma with brain metastasis: A case-series","volume":"3","author":"Mohler","year":"2021","journal-title":"Neuro-Oncol. Adv."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Sliwinska, M., Cieslak-Stec, M., Laprus, I., and Tarnawski, R. (2023). 482 Brain metastases in patients with advanced BRCA-associated ovarian cancer receiving systemic treatment and adjuvant maintenance Olaparib therapy according to the criteria of study 19 clinical trial\u2013single-centre experience. Int. J. Gynecol. Cancer.","DOI":"10.1136\/ijgc-2023-ESGO.587"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"73","DOI":"10.3892\/mco.2020.2035","article-title":"Long-term response to Olaparib in carcinomatous meningitis of a BRCA2 mutated ovarian cancer: A case report","volume":"13","author":"Favier","year":"2020","journal-title":"Mol. Clin. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s10147-019-01556-1","article-title":"Leptomeningeal metastases arising from gynecological cancers","volume":"25","author":"Yano","year":"2020","journal-title":"Int. J. Clin. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Jang, A.I., Bernstock, J.D., Segar, D.J., Distasio, M., Matulonis, U., and Bi, W.L. (2021). Case report: Frontoparietal metastasis from a primary Fallopian tube carcinoma. Front. Surg., 8.","DOI":"10.3389\/fsurg.2021.594570"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1136\/ijgc-2021-003053","article-title":"Evaluation of patterns of progression on poly (ADP-ribose) polymerase inhibitor (PARPi) maintenance in ovarian cancer: A cross-sectional study","volume":"32","author":"Cerda","year":"2022","journal-title":"Int. J. Gynecol. Cancer Off. J. Int. Gynecol. Cancer Soc."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1136\/ijgc-2023-004740","article-title":"Systemic therapy de-escalation in advanced ovarian cancer: A new era on the horizon?","volume":"33","author":"Caruso","year":"2023","journal-title":"Int. J. Gynecol. Cancer Off. J. Int. Gynecol. Cancer Soc."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1016\/S0090-8258(21)00693-4","article-title":"Long-term safety and secondary efficacy endpoints in the ENGOT-OV16\/NOVA phase III trial of niraparib in recurrent ovarian cancer","volume":"162","author":"Matulonis","year":"2021","journal-title":"Gynecol. Oncol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/14\/7887\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:19:19Z","timestamp":1760109559000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/14\/7887"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,18]]},"references-count":43,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2024,7]]}},"alternative-id":["ijms25147887"],"URL":"https:\/\/doi.org\/10.3390\/ijms25147887","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,18]]}}}